Tenecteplase for acute ischemic stroke

International Journal of Stroke

Volumn 6, Issue 6, 2011, Pages 509-510

  Lyden, Patrick ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TENECTEPLASE;

BOLUS INJECTION; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CORONARY ARTERY THROMBOSIS; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; HUMAN; IN VIVO STUDY; NONHUMAN; NOTE; PRIORITY JOURNAL; RECANALIZATION;

BRAIN ISCHEMIA; CORONARY THROMBOSIS; DRUG DESIGN; FIBRINOLYTIC AGENTS; HUMANS; SAFETY; STROKE; TISSUE PLASMINOGEN ACTIVATOR;

EID: 82255192757     PISSN: 17474930     EISSN: 17474949     Source Type: Journal    
DOI: 10.1111/j.1747-4949.2011.00695.x     Document Type: Note

References (20)

1. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995; 333:1581-7.
2. Lyden PD (ed). Thrombolytic Therapy for Stroke. Totowa, NJ: Humana Press, 2001.
3. Stewart RJ, Fredenburgh JC, Leslie BA, Keyt BA, Rischke JA, Weitz JI. Identification of the mechanism responsible for the increased fibrin specificity of TNK-tissue plasminogen activator relative to tissue plasminogen activator. J Biol Chem 2000; 275:10112-20.
4. Verstraete M. Third Generation Thrombolytic Drugs. Am J Med 2000; 109:52-8.
5. Keyt BA, Paoni NF, Refino CJ et al. A faster acting and more potent form of tissue plasminogen activator. Proc Natl Acad Sci USA 1994; 91:3670.
6. Cannon CP, Gibson CM, McCabe CS et al. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocrdial infarction. Circulation 1998; 98:2805.
7. Collen D, Stassen J, Yasuda T et al. Comparative thrombolytic properties of tissue-type plasminogen activator and of plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog. Thromb Haemost 1994; 72:98.
8. Thomas GR, Thibodeaux H, Errett CJ et al. A long-half-life and fibrin-specific form of tissue plasminogen activator in rabbit models of embolic stroke and peripheral bleeding. Stroke 1994; 25:2072.
9. Benedict CR, Refino CJ, Keyt BA et al. New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPA. Circulation 1995; 92:3032.
10. Zivin JA, Fisher M, DeGirolami U, Hemenway CC, Stashak JA. Tissue plasminogen activator reduces neurological damage after cerebral embolism. Science 1985; 230:1289.
11. Lapchak PA. Translational stroke research using a rabbit embolic stroke model: a correlative analysis hypothesis for novel therapy development. Transl Stroke Res 2010; 1:96-107.
12. Lapchak PA, Araujo DM, Zivin JA. Comparison of tenecteplase with alteplase on clinical rating scores following small clot embolic strokes in rabbits. Exp Neurol 2004; 185:154.
13. Chapman DF, Lyden P, Lapchak PA, Nunez S, Thibodeaux H, Zivin J. Comparison of TNK with wild-type tissue plasminogen activator in a rabbit embolic stroke model. Stroke 2001; 32:748.
14. Cannon CP, McCabe CS, Gibson CM et al. TNK-tissue plasminogen activator in acute myocardial infarction. Circulation 1997; 95:351.
15. Van de Werf F, Cannon CP, Luyten A et al. Safety assessment of single bolus administration of TNK-tPA in acute myocardial infarction: the ASSENT-1 trial. Am Heart J 1999; 137:786.
16. Van De Werf F, Adgey J, Ardissino D et al. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet 1999; 354:716-22.
17. Van de Werf F, Barron HV, Armstrong PW et al. Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents. Eur Heart J 2001; 22:2253.
18. Haley EC Jr, Lyden PD, Johnston KC, Hemmen TM. A pilot dose-escalation safety study of tenecteplase in acute ischemic stroke. Stroke 2005; 36:607-12.
19. Haley EC Jr, Thompson JL, Grotta JC et al. Phase IIB/III trial of tenecteplase in acute ischemic stroke: results of a prematurely terminated randomized clinical trial. Stroke 2010; 41:707-11.
20. Parsons MW, Miteff F, Bateman GA et al. Acute ischemic stroke: imaging-guided tenecteplase treatment in an extended time window. Neurology 2009; 72:915-21.